Clinical trialPhase 1Completed
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
A Phase 1 Study of Irreversible Electroporation and Pembrolizumab Immunotherapy in Locally Advanced Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 10 April 2024
- Expected end
- 15 September 2025
- Enrollment
- 2 participants
- Sites
- 1
- Primary outcomes
- Safety and Tolerability
- Sponsor
- Other
- Results posted
- No
- Last update
- 9 February 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).